Close Menu

NEW YORK – Vedanta Biosciences announced on Tuesday that it would kick off the first-in-patient clinical study of VE800 in combination with Bristol-Myers Squibb's nivolumab (Opdivo) in patients with advanced or metastatic melanoma, gastric or gastroesophageal junction adenocarcinoma, or microsatellite-stable colorectal cancer.

Vedanta is a clinical-stage biopharmaceutical company focused on creating treatments for immune-related diseases using human microbiome-derived bacteria.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jan
28

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.